Interpace Diagnostics to Present at NobleCon13
IT Business Net The Company currently has three commercialized molecular tests; PancraGen® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation ... |
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2j7fSTV
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου